Pedplot

Reta plotter

Half-life estimate, not bloodwork or dosing advice. Disclaimer.

t½ 6dTmax 2d100% parent

The prefilled numbers are an example input to draw the curve, not a dose; Pedplot does not suggest one. To step a dose up, add another row of the same compound with a later start day.

Peaks, troughs, and half-life
Not a blood level. The chart shows the estimated milligrams of the drug still in the body, so it will not match a lab result in ng/dL. How the model works. Washout continues after the last dose. Mixed IU and mg protocols are not summed.

Retatrutide

Peak

3.60 mg

Trough

2.02 mg

Swing

44%

~Steady state

35d

~Washout

32.5d

Saved locally
Stored in localStorage on this device. Reload a saved protocol from this list.

No saved protocols in this browser yet.

Investigational GIP, GLP-1 and glucagon triple agonist. Weekly doses overlap much like tirzepatide. There is no ester, so the line is the dose itself. Also called Retatrutide.

Half-life6d
Time to peak2d
Parent hormone100%
Example input2 mg
Example frequencyonce a week
Example length8 weeks
Data qualityMedium

Phase 1b trial (Urva et al. 2022, Lancet, abstract): half-life ~6 days. No published Tmax; 2 d is an estimate. How the model works.

The example curve

2 mg once a week for 8 weeks. With a 6d half-life, it levels off around day 35. The row runs longer than that, so the plateau is on the chart. Between doses it runs from about 2.02 to 3.6 mg, a swing of 44%. Each dose is its own spike. After the last dose, the tail takes about 32.5 days to fall to a few percent.

Mounjaro1 day shorter (5d vs 6d).

Sources

  1. Paper. Urva et al. 2022, Lancet (abstract): half-life approximately 6 days
  2. Community estimate. Tmax estimate; no published figure found